Skip to main content
S&P 5007,568.61+0.36%DOW51,745.70-0.46%NASDAQ25,378.24+0.85%BTC$77,723.00+1.02%ETH$2,284.16+1.48%GOLD$3,932.10-0.94%OIL$96.66+0.21%
Smart Investors Daily
SID Premium
NA

NASDAQ · NAGE

Niagen Bioscience Inc

Healthcare · Biotechnology

$2.40

Down-$0.06 (-2.29%)

Updated Nov 3, 2026, 8:31 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
529.91M
P/E ratio
29.68
Dividend yield
0.00%
52-week range
$2.32 – $5.40
Volume
558.89K
Avg. volume
1.04M

Price performance · NAGE

NAGE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

NAGE closed at $2.40 after 21 trading sessions, down 10.45% for the selected period.

Last close
$2.40
Period change
-10.45%
Period low
$2.33
Period high
$2.72
Daily close
View OHLC price history
NAGE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$2.36$2.41$2.35$2.40558.89K
Oct 30, 2026$2.49$2.49$2.32$2.33526.36K
Oct 29, 2026$2.58$2.58$2.50$2.50348.38K
Oct 28, 2026$2.46$2.55$2.46$2.54363.92K
Oct 27, 2026$2.46$2.515$2.425$2.50473.48K
Oct 26, 2026$2.43$2.45$2.385$2.44405.83K
Oct 23, 2026$2.50$2.50$2.42$2.43543.77K
Oct 22, 2026$2.46$2.525$2.46$2.52502.4K
Oct 21, 2026$2.52$2.52$2.425$2.47652.26K
Oct 20, 2026$2.50$2.535$2.48$2.51518.62K
Oct 19, 2026$2.49$2.52$2.435$2.50508.79K
Oct 16, 2026$2.58$2.5888$2.46$2.49556.11K
Oct 15, 2026$2.545$2.60$2.53$2.58446.34K
Oct 14, 2026$2.55$2.59$2.51$2.53522.86K
Oct 13, 2026$2.63$2.64$2.55$2.58636.47K
Oct 12, 2026$2.67$2.68$2.60$2.63410.11K
Oct 9, 2026$2.68$2.71$2.665$2.69268.12K
Oct 8, 2026$2.71$2.71$2.61$2.66635.19K
Oct 7, 2026$2.67$2.755$2.65$2.72361.11K
Oct 6, 2026$2.67$2.705$2.66$2.69373.38K
Oct 5, 2026$2.79$2.79$2.665$2.68865.14K

Latest NAGE news

The latest Smart Investors Daily articles mentioning NAGE.

Stock researchCompany · Overview

NAGE research

Overview

Company profile and research snapshot.

Company profile

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.00
Implied upside
—
Analysts
—
NAGE recent ratings
DateFirmRatingTarget
Oct 30, 2026Canaccord GenuityBuy—
May 11, 2026HC Wainwright & Co.Buy—
May 5, 2026Canaccord GenuityBuy—
Mar 31, 2026Canaccord GenuityBuy—
Mar 5, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product

LOS ANGELES, October 20, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by the Niagen® Skincare Innovation Lab. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen® (patented nicotinamide riboside, or NR

Yahoo · Oct 15, 2026

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

LOS ANGELES, October 15, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesda

Yahoo · Oct 8, 2026

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

LOS ANGELES, October 08, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, as the winner of the 2026 Annette Dickinson Trailblazer Award.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By